La Jolla Pharmaceutical Co.
(NASDAQ : LJPC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
1.22%303.041.4%$588.11m
AMGNAmgen, Inc.
0.21%233.901.3%$519.01m
GILDGilead Sciences, Inc.
1.93%67.201.0%$370.61m
REGNRegeneron Pharmaceuticals, Inc.
1.03%372.122.6%$303.57m
VRTXVertex Pharmaceuticals, Inc.
-0.02%223.021.9%$268.06m
ILMNIllumina, Inc.
2.24%326.983.5%$238.31m
ARWRArrowhead Pharmaceuticals, Inc.
2.90%67.4312.0%$192.64m
EXASEXACT Sciences Corp.
3.55%86.5824.0%$184.78m
CLVSClovis Oncology, Inc.
11.51%9.8814.7%$180.78m
ALXNAlexion Pharmaceuticals, Inc.
5.51%113.342.0%$179.50m
SRPTSarepta Therapeutics, Inc.
-0.29%109.6514.6%$148.41m
AAgilent Technologies, Inc.
0.68%82.081.6%$141.44m
BMRNBioMarin Pharmaceutical, Inc.
0.69%80.634.3%$130.99m
SGENSeattle Genetics, Inc.
0.43%117.666.1%$128.43m
NBIXNeurocrine Biosciences, Inc.
-0.48%115.935.0%$126.96m

Company Profile

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla's investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.